Renaissance Capital logo

Tang Capital Acquisition

Filed Terms, Nasdaq: TCAA

Blank check company formed by Tang Capital targeting clinical-stage biotechs.

Industry: SPAC

Tang Capital Acquisition Corp., or TCAA, is a newly formed company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to as our initial business combination. TCAA is, we believe, the first no-promote special purpose acquisition company, or np-SPAC, as described on the cover of this prospectus, and is structured to more closely align the interests of the SPAC sponsor with the SPAC investors. We have not selected any specific business combination target, and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We will have 24 months from the effectiveness of the registration statement of which this prospectus forms a part to complete our initial business combination, which we refer to as the completion window. While we may pursue an initial business combination target in any business or industry, we intend to focus our search in the biopharmaceutical industry.
IPO Data
IPO File Date 10/06/2026
Offer Price n/a
Price Range $25.00 - $25.00
Offer Shares (mm) 3.0
Deal Size ($mm) $75
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Underwriter Name LifeSci Capital
Underwriter Name Raymond James
Company Data
Headquarters San Diego, CA, United States
Founded 2026
Employees at IPO 5

Tang Capital Acquisition (TCAA) Performance